Trial Profile
A Phase I/IIa Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transgene
- 28 Mar 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 11 Mar 2020 Planned End Date changed from 1 Oct 2019 to 1 Sep 2020.
- 11 Mar 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Sep 2020.